ScreenerHero

CYTK Cytokinetics, Incorporated

NAS · US · Healthcare · Biotechnology · cytokinetics.com
61.35USD-2.15%Mkt Cap: 8.53B $P/E: —

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the Unit…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap8.53B USD
Enterprise Value9.38B USD
Revenue (TTM)67.67M USD
Gross Profit-327.99M USD
Net Income (TTM)-784.96M USD
Revenue/Share0.54 USD
Last Price61.35 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees673
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.74
PEG—
EV/EBITDA-13.49
EV/Revenue138.59
P/S134.77
P/B-52.48
EPS (TTM)-7.22
EPS (Forward)-4.45
52W Range
47.2234% of range88.31
52W High88.31 USD
52W Low47.22 USD
Profitability
Gross Margin-372.55%
Oper. Margin-625.95%
EBITDA Margin0.00%
Profit Margin-891.60%
ROE119.00%
ROA-55.10%
Growth
Revenue Growth-57.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-510.01M USD
CapEx (TTM)24.81M USD
FCF Margin-587.27%
FCF Yield-4.66%
Net Debt258.77M USD
Net Debt/EBITDA-0.37
Balance Sheet
Debt/Equity-1.95
Current Ratio6.66
Quick Ratio6.56
Book Value/Sh-1.25 USD
Cash/Share8.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 25, 2013
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)109.90 USD
Upside (mean)+79.1%
Target Range85.00 USD – 146.00 USD
85.00+79.1% to mean146.00
# Analysts20
Ownership
Shares Out.139.02M
Float138.49M
Insiders0.64%
Institutions125.99%
Short Interest
Short Ratio9.9d
Short % Float19.20%
Short % Out.12.57%
Shares Short17.48M
Short (prev mo.)16.32M
Technical
SMA 5073.62 (-16.7%)
SMA 20070.15 (-12.5%)
Beta0.36
S&P 52W Chg14.58%
Avg Vol (30d)2.07M
Avg Vol (10d)2.18M
Technical Indicators
RSI (14)25.6
MACD-3.1320
MACD Signal-2.8183
MACD Hist.-0.3137
BB Upper76.41 USD
BB Middle68.22 USD
BB Lower60.03 USD
BB Width24.01%
ATR (14)2.456 USD
Vol Ratio (20d)1.50x